Drug Trial News

RSS

Combination of Abraxane and gemcitabine improves survival of patients with pancreatic cancer

A new cancer drug combination demonstrated significant improvement in overall survival of late-stage pancreatic cancer patients compared to those receiving standard treatment, according to results of a Phase III clinical trial led by physicians from Scottsdale Healthcare's Virginia G. Cancer Center Clinical Trials, a partnership with the Translational Genomics Research Institute (TGen).

17 Nov 2012

Denosumab associated with improved overall survival in NSCLC patients

It is common for patients initially diagnosed with lung cancer to have the cancer spread to sites like the liver, brain and bone. One of the most frequent sites of metastases is the bone, with an estimated 30 to 40 percent of patients with non-small-cell lung cancer (NSCLC) developing bone loss.

16 Nov 2012

Positive results from POZEN’s PA8140-102 Phase 1 bioavailability study

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today that the results from a Phase 1 study, PA8140-102, demonstrated that PA8140, POZEN's proprietary combination of aspirin (81 mg) and omeprazole (40 mg), had comparable bioavailability relative to the reference listed product, enteric-coated (EC) aspirin (81 mg).

16 Nov 2012

RXi announces pharmacokinetic results from RXI-109 Phase 1 study in healthy subjects

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the pharmacokinetic results of their single dose Phase 1 study with RXI-109 in healthy subjects.

15 Nov 2012

Enrollment complete in Exact Sciences DeeP-C screening trial for colorectal cancer

Exact Sciences Corp. today announced it has completed patient enrollment in its DeeP-C pivotal trial for colorectal cancer screening. The study enrolled more than 12,700 patients at sites in the United States and Canada.

15 Nov 2012

Researchers describe structure of active site core of topoisomerase II alpha anti-cancer drug target

A group of researchers at the University of California, Berkeley have for the first time described the structure of the active site core of topoisomerase II alpha, an important target for anti-cancer drugs.

15 Nov 2012

Positive preliminary results from ImmunoPulse Phase II trial in metastatic melanoma

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, announces positive preliminary results from a Phase II trial investigating the use of ImmunoPulse in metastatic melanoma patients at the 6th World Meeting of Interdisciplinary Melanoma Skin Cancer Centres & 8th EADO Congress.

15 Nov 2012

Trastuzumab increases risk of heart failure in older women with breast cancer

Heart failure is a relatively common complication in older women with breast cancer, but the risk is even higher in those patients treated with adjuvant trastuzumab (Herceptin-), Yale School of Medicine researchers report in the current issue of the Journal of the American College of Cardiology.

15 Nov 2012

Paxvax PXVX0200 cholera vaccine demonstrates safety and immunogenicity in Phase 1 clinical trial

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner today announced results from a Phase 1 clinical trial of PaxVax's single-dose oral cholera vaccine candidate at the 2012 American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting in Atlanta.

15 Nov 2012

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of liver disease associated with AAT deficiency. These data were presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, "The Liver Meeting") held November 9-13, 2012 in Boston.

15 Nov 2012

Blog examines RTS,S malaria vaccine trial results

In a post in the Center for Global Development's (CGD) "Global Health Policy" blog, Owen Barder, a senior fellow and director for Europe at the CGD, reports on the results of a large Phase III clinical trial conducted in Africa on the malaria vaccine candidate RTS,S, published online in the New England Journal of Medicine on Friday.

14 Nov 2012

Tiltan Pharma initiates enrollment in TL-118 Phase 2 trial for metastatic pancreatic cancer

Tiltan Pharma Ltd. today announced that it has enrolled the first U.S. patient, at White Plains Hospital in Westchester County N.Y., in a Phase 2 clinical trial of its anti-angiogenic product, TL-118, for the treatment of metastatic pancreatic cancer.

14 Nov 2012

IDMC reviews data from Nanobiotix’s NBTXR3 Phase I study on advanced soft tissue sarcoma

Nanobiotix, announced today that the Independent Data Monitoring Committee (IDMC) has reviewed the data of the first 6 patients treated in the phase I Study with the lead product NBTXR3 for the treatment of advanced Soft Tissue Sarcoma of the extremity. Based on the review of the safety data, the IDMC has unanimously recommended continuing the enrollment in the study according to the protocol. This trial is realized in the Institut Gustave Roussy, France.

13 Nov 2012

Abbott releases details on phase 3 hepatitis C registrational program

Abbott today released details on its phase 3 hepatitis C registrational program following promising results from its phase 2b clinical trial, known as Aviator, presented at the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston.

13 Nov 2012

RTS,S vaccine candidate can help protect African infants against malaria

International African Vaccinology Conference, Cape Town, South Africa-Results from a pivotal, large-scale Phase III trial, published online today in the New England Journal of Medicine, show that the RTS,S malaria vaccine candidate can help protect African infants against malaria.

9 Nov 2012

Omeros to present results from first pivotal Phase 3 trial of OMS302 at AAO annual meeting

Omeros Corporation today reported that it will present data from its first pivotal Phase 3 clinical trial evaluating OMS302 at the American Academy of Ophthalmology (AAO) Annual Meeting, which will take place from November 10 through November 13 in Chicago, Illinois.

9 Nov 2012

Immunomic Therapeutics initiates JRC-LAMP-vax vaccine Phase I trial in Sugi allergy

Immunomic Therapeutics, Inc., a leader in developing novel allergy immunotherapies, announced today that it has dosed the first patient in a Phase I clinical trial of its lead candidate, JRC-LAMP-vax vaccine, at its clinical site in Honolulu, Hawaii. Initial subjects include Japanese ex-patriates previously exposed to Japanese red cedar, or "Sugi," as it is known in Japan.

9 Nov 2012

Positive results from Palatin’s bremelanotide Phase 2B trial on female sexual dysfunction

Palatin Technologies, Inc. today reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of female sexual dysfunction (FSD).

9 Nov 2012

Plexxikon updates Zelboraf Phase 1 data on BRAF V600E mutation-positive melanoma

Plexxikon today announced that updated Phase 1 clinical data of Zelboraf (vemurafenib) were presented at the Society for Melanoma Research (SMR) 2012 Congress, held November 8-11 in Los Angeles, CA.

8 Nov 2012

Patient recruitment complete for immatics IMA901 Phase 3 trial for renal cell carcinoma

immatics biotechnologies GmbH, a biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer, announced today that it has completed patient recruitment into the pivotal phase 3 trial evaluating its lead cancer vaccine IMA901 for renal cell carcinoma (RCC). The trial has completed patient inclusion and it is expected that around 345 patients will be randomized across 10 countries in the US and Europe.

8 Nov 2012

Drug Trial News

Combination of Abraxane and gemcitabine improves survival of patients with pancreatic cancer

Denosumab associated with improved overall survival in NSCLC patients

Positive results from POZEN’s PA8140-102 Phase 1 bioavailability study

RXi announces pharmacokinetic results from RXI-109 Phase 1 study in healthy subjects

Enrollment complete in Exact Sciences DeeP-C screening trial for colorectal cancer

Researchers describe structure of active site core of topoisomerase II alpha anti-cancer drug target

Positive preliminary results from ImmunoPulse Phase II trial in metastatic melanoma

Trastuzumab increases risk of heart failure in older women with breast cancer

Paxvax PXVX0200 cholera vaccine demonstrates safety and immunogenicity in Phase 1 clinical trial

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Blog examines RTS,S malaria vaccine trial results

Tiltan Pharma initiates enrollment in TL-118 Phase 2 trial for metastatic pancreatic cancer

IDMC reviews data from Nanobiotix’s NBTXR3 Phase I study on advanced soft tissue sarcoma

Abbott releases details on phase 3 hepatitis C registrational program

RTS,S vaccine candidate can help protect African infants against malaria

Omeros to present results from first pivotal Phase 3 trial of OMS302 at AAO annual meeting

Immunomic Therapeutics initiates JRC-LAMP-vax vaccine Phase I trial in Sugi allergy

Positive results from Palatin’s bremelanotide Phase 2B trial on female sexual dysfunction

Plexxikon updates Zelboraf Phase 1 data on BRAF V600E mutation-positive melanoma

Patient recruitment complete for immatics IMA901 Phase 3 trial for renal cell carcinoma

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News